Core Viewpoint - NLS Pharmaceutics Ltd. is undergoing a significant transition involving a reverse stock split and a merger with Kadimastem Ltd. to enhance its market position and expand its capabilities in developing therapies for rare and complex central nervous system disorders [1][2][3] Group 1: Reverse Stock Split - A reverse stock split is scheduled for October 31, 2025, consolidating every 10 shares of NLSP into 1 share [2] - The current stock price is $0.74, reflecting a recent decrease of 29.52% [2] - The new CUSIP number for shares post-merger and reverse split will be H5835A109 [3] Group 2: Merger with Kadimastem Ltd. - The merger with Kadimastem Ltd. will result in a name change to NewcelX Ltd. and a new symbol "NCEL" on the Nasdaq Capital Market [2] - This merger aims to expand NLS Pharmaceutics' capabilities in its specialized field [3] Group 3: Market Performance - NLSP's stock has fluctuated between a low of $0.74 and a high of $0.94 today, with a yearly peak of $4.74 [3] - The company's market capitalization is approximately $2.34 million, with a trading volume of 1,409,410 shares [3]

Ronen Twito, Executive Chairman and Chief Executive Officer of Kadimastem & Alexander Zwyer, Chief Executive Officer of NLS Pharmaceutics: NewCelX- Israel Science. Nasdaq Execution. Global Vision. "The AEX-6xx program significantly extends the translational scope of the DOXA platform," said Dr. Eric Konofal, Founder and Chief Scientific Officer at Aexon Labs and NLS. "We are encouraged by the robust behavioral and cellular data and are preparing for investigational new drug (IND)-enabling studies with stron ...

Accessibility StatementSkip Navigation ZURICH, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous system and neurodegenerative disorders, and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), a clinical-stage cell therapy company developing treatments for neurodegenerative diseases and diabetes today announced that the ITOL-102 cell therapy program for Type 1 Diabetes, originally ...

Accessibility StatementSkip Navigation The new CUSIP number for the Common Shares following the Merger and the Reverse Split will be H5835A109. A notice of the Reverse Split and other capital measures approved by the Company in connection with the Merger and the Reverse Split, will be filed with the commercial registry of the Canton of Zurich, Switzerland, on October 30, 2025. As a result, the Reverse Split will become effective in Switzerland on October 30, 2025, and will be reflected on Nasdaq at market o ...

Core Points - NLS Pharmaceutics Ltd. and Kadimastem Ltd. have received Nasdaq approval for the listing of the combined company's shares following the completion of their merger, set to close on October 30, 2025 [1][11] - The final exchange ratio for the merger is established at 7.06 NLS common shares for each Kadimastem ordinary share, which will adjust to 0.706 NLS common shares per Kadimastem ordinary share after a reverse share split [3] - The new entity will be named NewCelX Ltd. and will begin trading on the Nasdaq Capital Market under the ticker symbol "NCEL" starting October 31, 2025 [3] Company Information - NLS Pharmaceutics Ltd. is a Swiss-based biopharmaceutical company focused on developing innovative therapies for central nervous system disorders [5] - Kadimastem Ltd. is a clinical-stage cell therapy company that develops allogeneic, "off-the-shelf" cell products for neurodegenerative diseases and diabetes [6] Shareholder Information - Trading in Kadimastem's ordinary shares on the Tel Aviv Stock Exchange will be suspended until the shares are delisted upon merger completion, with final delisting scheduled for October 31, 2025 [2] - NewCelX common shares are expected to be deposited into Kadimastem shareholders' accounts by the end of the trading day on November 3, 2025, with trading expected to commence on November 4, 2025 [4]

Accessibility StatementSkip Navigation ZURICH, Oct. 23, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system ("CNS") disorders, and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), an advanced clinical-stage cell therapy company developing treatments for neurodegenerative diseases and diabetes, today announced an update regarding the proposed merger (the "Merger"). Ronen Twito, Ka ...

Core Viewpoint - The merger between NLS Pharmaceutics Ltd. and Kadimastem Ltd. has been approved by NLS shareholders, paving the way for the formation of NewCelX Ltd., which will be listed on Nasdaq under the ticker "NCEL" [1][6][7]. Group 1: Merger Details - The merger will create a Nasdaq-listed company named NewCelX, with governance and capital structure approvals completed [2]. - Kadimastem shareholders will own 84.4% of the combined company, while NLS shareholders will own 15.6%, reflecting the relative value contributions of each party [5][6]. - The combined company will integrate Kadimastem's advanced cell therapy programs with NLS's expertise in CNS small-molecule therapies [2][7]. Group 2: Leadership and Governance - The leadership team will be headed by Ronen Twito as Executive Chairman and CEO, with Prof. Michel Revel serving as Chief Scientific Officer and Director [3][6]. - A new Board of Directors will be elected, and various committees will be newly constituted to enhance governance and execution [6]. Group 3: Clinical Programs and Pipeline - The merger will unite Kadimastem's clinical programs, including a Phase 2a ALS trial of AstroRx® and the IsletRx diabetes product candidate, with NLS's CNS therapies [7]. - The combined company aims to build a diversified biotechnology portfolio with the potential to deliver transformative therapies to patients worldwide [7].

ZURICH and NESS ZIONA, Israel, Sept. 10, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq:Â NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system ("CNS") disorders, and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), an advanced clinical-stage cell therapy company progressing treatments for neurodegenerative diseases and diabetes, today announced that the U.S. Securities and Exchange Commission (the "SEC") has declared effective the registration st ...

Core Insights - Kadimastem has secured a patent in Hong Kong for its IsletRx technology, enhancing its global intellectual property (IP) portfolio, which already includes patents in Europe, the United States, and India [1][2][3] - The IsletRx platform aims to provide a scalable source of insulin-producing islet-like cells to address diabetes, a significant health challenge affecting millions globally [5][3] - The economic impact of diabetes in Hong Kong is substantial, with an estimated 706,000 adults affected, leading to lifetime healthcare costs averaging $125,000 per patient, translating to a potential economic burden of approximately $90 billion [3][4] Company Overview - Kadimastem Ltd. is a clinical-stage cell therapy company focused on developing allogeneic, "off-the-shelf" cell products for neurodegenerative diseases and diabetes [7] - NLS Pharmaceutics Ltd. is a Swiss-based biopharmaceutical company dedicated to innovative therapies for central nervous system disorders [6]

Revenue and Payments - The company received a non-refundable upfront payment of $2.5 million in 2019 under the EF License Agreement and is eligible for milestone payments of up to $16 million based on regulatory achievements [874]. - As of December 31, 2023, the company had long-term deferred revenues of $2.5 million related to the Nolazol product candidate, which will be recognized upon completion of development services and regulatory approval in Latin America [874]. - The EF License Agreement with Eurofarma will be terminated effective September 30, 2024, with the company recognizing $2.5 million as other income due to this termination [875]. - The company’s revenue recognition follows ASC 606, which requires the identification of promised goods or services and the measurement of transaction prices [872]. Pension and Tax Liabilities - As of December 31, 2024, the company has no net pension-related liability or associated pension expense recognized on its balance sheet, as all obligations related to the prior pension plan have been settled [876]. - The company incurs tax loss carryforwards generating deferred tax assets, but a full valuation allowance is recognized as it is not likely that the tax benefits can be realized [877]. - The company has a single fully insured collective pension plan, with no active employees participating as of December 31, 2024 [876]. Foreign Currency Exposure - Approximately 59.3% of the company's expenses for the year ended December 31, 2024, were denominated in CHF, 6.4% in EUR, and 0.1% in GBP, indicating significant foreign currency exposure [865]. - Changes of 5.0% and 10.0% in the U.S. dollar/CHF exchange rate would have increased/decreased operating expenses by 3.0% and 6.0%, respectively [865]. - The company does not hedge its foreign currency exchange risk but may consider formal currency hedging transactions in the future [867].